logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2020 – Phase 3 trial follow-up confirms venetoclax-obinutuzumab in patients with previously untreated CLL

A more efficient regimen may be in sight for “typical” patients with newly diagnosed chronic lymphocytic leukemia.